Infusion

COVID-19 Monoclonal Antibody Treatment



PATIENT INFORMATION		
Patient Name:	DOB:	
Date: Allergies:		
Follow-up Provider (if different than ordering provider):		
Is the patient in a SNF? $\ \square$ No $\ \square$ Yes		
ORDERS PRECEDED BY A ■ REQUIRE A ⊠ TO INITIATE THE ORDER.		
DOSE:		
Medication and dosing per pharmacy availability and Emergency Use Authorization (EUA) parameters. An antibody may not be available for all patient groups / categories depending on currently available and authorized medications. There are currently no approved COVID-19 monoclonal antibody therapies for children under the age of 12 OR for post exposure prophylaxis. Qualification/requirements to receive COVID-19 Monoclonal Antibody Therapy at Salem Health (if ANY of the following are not answered, the order cannot be processed. For statements allowing for only one yes/no answer, that is the ONLY approved answer to that statement.): Place X inside box for all that apply		
Patient has a positive COVID-19 test? \Box YES \Box NO (If the answer is NO, the treatment option for post exposure prophylaxis.)	ne patient cannot receive treatment. We currently do not have a	
 □ The patient is within 7 days of the onset of symptoms. Date of onset of sympatient weight	ID-19 east one of the following (select all that apply, must have at least one) efibrosis and pulmonary HTN) hat confer medical complexity (ex: genetic or metabolic syndromes astrostomy, or positive pressure ventilation [not related to COVID-19])	
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/ I have discussed with the patient the contents of the Fact Sheet for Patients, Pare "YES" **Providers must educate to the contents of the fact sheet for patients of the fact sheet for patients of the medication specific EUA document itself.	nts and Caregivers before the patient has received the infusion.	
I have informed the patient that they should not receive a COVID vaccine for at \ensuremath{T}	least 90 days following this infusion. □ YES	
I have informed the patient that this drug is experimental, and of the risks and	· · · · · · · · · · · · · · · · · · ·	
The patient has given verbal consent to receive COVID-19 Monoclonal Antibody	rTherapy? □ YES	
Pre-meds (drug, dose, and route): (Select ONLY those that apply) * Patients should be instructed to take oral medications ½ hour before appoi Diphenhydramine (check one) □ 25mg IV □ 50mg IV If not already take □ Tylenol 650 mg PO if not already taken prior to arrival □ Ondansetron 4mg IV PRN Nausea □ Dexamethasone IV mg □ Other (drug, dose, route and frequency)		
Frequency of Pre-medication □ ONCE □ PRN		

salemhealth.org Infusion

Appointment line: 503-814-8210 Fax: 503-814-1465 Clinic Hours:

Infusion

COVID-19 Monoclonal Antibody Treatment



ORDERS PRECEDED BY A \blacksquare REQUIRE A $oxtimes$ TO INITIATE THE ORDER.		
Patients with central line access:		
Select one: □ Patient has a PICC □ Implanted port □ Other CVAD □ Patient does not have a CVAD		
🗵 Central line care per Salem Health CVAD Access Policy. (Lippincott). May use alternative dressing or cleanser for skin breakdown.		
Alteplase per Salem Health Central Venous Access Device de-clotting (Lippincott) for S/sx of occlusion: Inability to infuse fluids, no blood return, increased resistance when flushing, increased occlusion/high-pressure alarm when using an infusion pump, sluggish gravity flow		
■ 1 View Chest X-ray to verify PICC tip location PRN for: Catheter migration greater than 5 cm, signs and symptoms of tip malposition (occlusion unresolved by Alteplase, discomfort in the arm, neck or chest, unusual sensations or sounds when flushing, neck vein engorgement, or heart palpitations.) Notify Physician or Provider if implemented		
☑ Notify physician if infusion NOT given or patient is a 'No Show' for his or her appointment.		
☑ Follow SH Infusion reaction protocol for symptom of infusion reaction. Notify provider if implemented		
Provider Signature Provider Printed Name Date:		